secwatch.observer — SEC 8-K summary
======================================

Issuer:     Akebia Therapeutics, Inc. (AKBA)
CIK:        0001517022
Form:       8-K
Filed at:   2023-06-13T23:59:59+00:00
Accession:  0001517022-23-000017
Event type: leadership
Sentiment:  neutral
Materiality: 0.70
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

CFO David Spellman resigns; Ellen Snow appointed as new CFO effective July 17, 2023
--------------------------------------------------------------------------------

- David Spellman resigns as CFO, effective June 23, 2023; will receive 12 months base salary continuation and COBRA reimbursement.
- Ellen Snow appointed SVP, CFO, Treasurer effective July 17, 2023; base salary $450k, bonus 45% target, equity grants (560k options, 370k RSUs).
- CEO John Butler serves as interim principal financial officer from June 23 to July 17, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1517022/000151702223000017/0001517022-23-000017-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1517022/000151702223000017/akba-20230609.htm
  HTML page:      https://secwatch.observer/filing/0001517022-23-000017

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer